• Medipal and JCR Pharmaceuticals dosed the first patient in a global Phase I/II trial of JR-446 for MPS IIIB.
• Results have not been presented; the study will assess safety, tolerability, and early signs of benefit.
• Medipal holds commercialization rights for JR-446 outside Japan, shaping potential future revenue if development succeeds.
• JCR is running the global program as sponsor; a separate Phase I/II study remains ongoing in Japan.
• The drug received orphan designations in the US, EU, and Japan in 2025, supporting a clearer regulatory path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipal Holdings Corporation published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.